Clearside Biomedical, Inc. Cashflow Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021	FY2020 12 months to Dec 31, 2020
Operating activities
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Non-cash interest expense on liability related to the sales of future royalties, net of issuance costs accretion
Depreciation
Share-based compensation expense
Change in fair value of warrant liabilities
Issuance costs allocated to warrant liabilities
Amortization and accretion of available-for-sale investments, net
Gain on termination of operating lease
Loss on disposal of fixed assets
Amortization and accretion on available-for-sale investments, net
Gain on extinguishment of debt
Non-cash interest expense
Accretion of debt discount

Changes in operating assets and liabilities:
Accounts receivable, prepaid expenses and other current assets
Other assets and liabilities
Accounts payable and accrued liabilities (includes $248 and $82 to a related party for the year ended December 31, 2024 and 2023, respectively)
Deferred revenue
Net cash used in operating activities
Investing activities
Maturities of available-for-sale-investments
Purchase of short-term investments
Maturity of short-term investments
Acquisition of property and equipment
Net cash used in investing activities

Financing activities
Proceeds from issuance of common stock and warrants in registered direct offering, net of issuance costs
Proceeds from royalty purchase and sale agreement, net of $1,862 of issuance costs
Payments on royalty purchase and sale agreement
Proceeds from at-the-market sales agreement, net of issuance costs
Proceeds from private placement, net of issuance costs
Proceeds from registered direct offering, net of issuance costs
Proceeds from shares issued under employee stock purchase plan
Proceeds from exercise of stock options
Proceeds from issuance of long-term debt
Principal payments made on long-term debt
Net cash provided by financing activities

Net (decrease) increase in cash, cash equivalents and restricted cash
Cash, cash equivalents and restricted cash, beginning of period
Cash, cash equivalents and restricted cash, end of period
Supplemental disclosure
Interest paid
Purchase of property and equipment in accounts payable and accrued liabilities
Forgiveness of PPP Loan and accrued interest
Reconciliation of cash, cash equivalents and restricted cash:
Cash and cash equivalents
Restricted cash (recorded in other current assets)

Comments